Regional Intravenous Ketanserin and Guanethidine Therapy in Raynaud's Phenomenon

Abstract

The authors report the results of a study of 25 patients with Raynaud's phenomenon (primary, posttraumatic, and secondary to diffuse connective tissue deseases) treated with regional intravenous injections of guanethidine or ketanserin. These two drugs were chosen because of the different etiopathologic profiles of the conditions.

All the patients showed a substantial clinical improvement with a remission of trophic lesions.

Conditions secondary to connective tissue disorders did not demonstrate much improvement based on instrumental data alone, possibly because of the intrinsic limitations of the techniques used for evaluating peripheral blood flow.

This specific type of pharmaceutical treatment appeared to be especially suitable for this disease owing to a combination of therapeutic efficacy and a substantial reduction in the total dosage for each patient.

Get full access to this article

View all access options for this article.

References

Hannington-Kiff JG ; Intravenous regional sympathetic block with guanethidine. Lancet 1:1019-1020, 1974 .

Olshwang D. , Beer G. , Magora F. : Intravenous regional guanethidine treatment in peripheral vascular diseases . Angiology 31:639-645, 1980.

Glynn CJ , Basedow RW , Walsh JA : Pain relief following post-ganglionic sympathetic blockade with i.v. guanethidine . Br J Anaesth 53:1297, 1981.

Eriksen S. : Duration of sympathetic blockade. Stellate ganglion versus regional guanethidine block. Anaesthesia 36:768, 1981.

Driessen JJ , Van Der Werken CHR , Nicolai Jpa , Crul JF : "Clinical effects of regional intravenous guanethidine (Ismelin) in reflex sympathetic dystrophy." Acta Anaesth Scand 27:505-509, 1983.

Caputi CA , Fogliardi A. , Busca G. , De Carolis G. : Clinical and instrumental evaluation of i.v. regional treatment with sympatholytic drugs in peripheral vascular diseases. Clin Trials J 22:257-262, 1985.

Caputi CA , De Carolis G. , Braccioni U. : Blocco intraarterioso e intravenoso farmacologico regionale quale approccio diagnostico e terapeutico in pazienti affetti da sindromi acrospastiche. Acta Cardiol Mediter 3:401-405, 1985.

Vanhoutte PM : 5-Hydroxytryptamine and vascular diseases. Fed Proc 42:223-227, 1983.

Janssen Pharmaceutic : Ketanserin: a novel serotonin S-2 receptor blocking agent. Investigational New Drug Brochure, ed. 7,1983.

10.

Janssen PA : Pharmacology of potent and selective S-2 serotoninergic antagonists. J Cardiovasc Pharm 7:2-11, 1985.

11.

Boas RA : Intra arterial peripheral vascular disease. Angiology 37:267-271, 1986.

12.

Bounameaux M. , Holditch T. , Hellemans H. , et al: Placebo controlled, double-blind, two-centre trial of ketanserin in intermittent claudication. Lancet 2:1268-1271, 1985.

13.

Standen E. , Roald OK , Krohg K. : Treatment of Raynaud's phenomenon with the 5HT-2 receptor antagonist ketanserin . Br Med J 285:1969-1971, 1982 .

14.

Seibold JR , Jageneau Ahm : Treatment of Raynaud's phenomenon with Ketanserin, a selective antagonist of the serotonin 2 (5HT-2) receptor, Arthritis Rheun 27: 139-145,1984.

15.

Roald OK , Seem E. : Trattamento del fenomeno di Raynaud con ketanserina in pazienti affetti da connettiviti diffuse. Br Med J (Ed Ital) 1:318-320, 1984.

16.

Jalpern A. , Kunh PH , Shaftel HE , et al: Raynaud's phenomenon and serotonin. Angiology 11:151-167, 1960.

17.

Seibold JR : Serotonin and Raynaud's phenomenon. J Cardiovasc Pharm 7:95-98, 1985.

18.

Tabira T. , Shibasaki H. , Kuraiwa Y. : Reflex sympathetic dystrophy (causalgia) treatment with guanethidine. Arch Neurol 40:430-432, 1983.

19.

Woosley R. , Nies AS : Drug therapy: Guanethidine. N J Med 295:1052, 1976 .